1. Home
  2. WVE vs NAGE Comparison

WVE vs NAGE Comparison

Compare WVE & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • NAGE
  • Stock Information
  • Founded
  • WVE 2012
  • NAGE 1999
  • Country
  • WVE Singapore
  • NAGE United States
  • Employees
  • WVE N/A
  • NAGE N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • NAGE Medicinal Chemicals and Botanical Products
  • Sector
  • WVE Health Care
  • NAGE Health Care
  • Exchange
  • WVE Nasdaq
  • NAGE Nasdaq
  • Market Cap
  • WVE 915.6M
  • NAGE 861.0M
  • IPO Year
  • WVE 2015
  • NAGE N/A
  • Fundamental
  • Price
  • WVE $8.29
  • NAGE $9.41
  • Analyst Decision
  • WVE Strong Buy
  • NAGE Strong Buy
  • Analyst Count
  • WVE 17
  • NAGE 3
  • Target Price
  • WVE $19.94
  • NAGE $17.00
  • AVG Volume (30 Days)
  • WVE 2.2M
  • NAGE 922.2K
  • Earning Date
  • WVE 07-30-2025
  • NAGE 10-30-2025
  • Dividend Yield
  • WVE N/A
  • NAGE N/A
  • EPS Growth
  • WVE N/A
  • NAGE N/A
  • EPS
  • WVE N/A
  • NAGE 0.22
  • Revenue
  • WVE $93,946,000.00
  • NAGE $116,303,000.00
  • Revenue This Year
  • WVE N/A
  • NAGE $28.46
  • Revenue Next Year
  • WVE $10.02
  • NAGE $21.65
  • P/E Ratio
  • WVE N/A
  • NAGE $43.72
  • Revenue Growth
  • WVE N/A
  • NAGE 35.90
  • 52 Week Low
  • WVE $5.04
  • NAGE $3.13
  • 52 Week High
  • WVE $16.74
  • NAGE $14.69
  • Technical
  • Relative Strength Index (RSI)
  • WVE 41.39
  • NAGE 40.69
  • Support Level
  • WVE $7.12
  • NAGE $9.50
  • Resistance Level
  • WVE $10.45
  • NAGE $9.97
  • Average True Range (ATR)
  • WVE 0.54
  • NAGE 0.40
  • MACD
  • WVE -0.24
  • NAGE 0.00
  • Stochastic Oscillator
  • WVE 33.82
  • NAGE 25.45

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About NAGE Niagen Bioscience Inc. Common Stock

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Share on Social Networks: